Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

A New Subcutaneous Immunoglobulin 20% Formulation (SCIG 20%) with Individualized Infusion Parameters Resulted in a Positive Safety and Tolerability Profile in Patients with PIDD in Europe and North America

Suez, Daniel ; Krivan, Gregely ; Jolles, Stephen R. ; Hussain, Iftikhar ; Stein, Mark R. ; Gupta, Sudhir ; Paris, Kenneth ; Hagen, Martin van ; Brodszki, Nicholas LU and McCoy, Barbara , et al. (2017) 2017th AAAAI Annual Meeting In Journal of Allergy and Clinical Immunology 139(2, Supplement). p.216-216
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; and (Less)
publishing date
type
Contribution to journal
publication status
published
subject
in
Journal of Allergy and Clinical Immunology
volume
139
issue
2, Supplement
article number
682
pages
216 - 216
publisher
Elsevier
conference name
2017th AAAAI Annual Meeting
conference location
Atlanta, United States
conference dates
2017-03-03 - 2017-03-06
ISSN
0091-6749
DOI
10.1016/j.jaci.2016.12.700
language
English
LU publication?
no
additional info
Programs and Abstracts of Papers to be Presented During Scientific Sessions: 2017 AAAAI Annual Meeting.
id
baf44f27-22ff-4b14-88f1-4cfc9c2e45be
alternative location
https://www.sciencedirect.com/science/article/pii/S0091674916322187
date added to LUP
2021-10-11 14:52:11
date last changed
2021-10-12 07:37:02
@misc{baf44f27-22ff-4b14-88f1-4cfc9c2e45be,
  author       = {{Suez, Daniel and Krivan, Gregely and Jolles, Stephen R. and Hussain, Iftikhar and Stein, Mark R. and Gupta, Sudhir and Paris, Kenneth and Hagen, Martin van and Brodszki, Nicholas and McCoy, Barbara and Yel, Leman}},
  issn         = {{0091-6749}},
  language     = {{eng}},
  note         = {{Conference Abstract}},
  number       = {{2, Supplement}},
  pages        = {{216--216}},
  publisher    = {{Elsevier}},
  series       = {{Journal of Allergy and Clinical Immunology}},
  title        = {{A New Subcutaneous Immunoglobulin 20% Formulation (SCIG 20%) with Individualized Infusion Parameters Resulted in a Positive Safety and Tolerability Profile in Patients with PIDD in Europe and North America}},
  url          = {{http://dx.doi.org/10.1016/j.jaci.2016.12.700}},
  doi          = {{10.1016/j.jaci.2016.12.700}},
  volume       = {{139}},
  year         = {{2017}},
}